Uterine fibroids are benign (non-cancerous) smooth-muscle tumors that grow from the wall of the uterus. They are extraordinarily common — affecting up to 70–80% of women by age 50 — yet most fibroids cause no symptoms and have no meaningful impact on fertility.
The challenge lies in identifying the minority of fibroids that do matter for conception and understanding when surgical removal genuinely improves outcomes versus when it adds risk without benefit.
Types of Uterine Fibroids and Their Fertility Impact
Fibroids are classified by their location relative to the uterine wall and cavity. Location is far more important than size when it comes to fertility impact.
| Fibroid Type | Location | Fertility Impact |
|---|---|---|
| Submucosal (type 0–2) | Protrudes into or distorts the uterine cavity | Most significant — reduces implantation and live birth rates |
| Intramural | Within the uterine wall; may distort cavity | Moderate impact when large or distorting cavity |
| Intramural (non-distorting) | Within wall; cavity not distorted | Minimal to no proven impact on IVF outcomes |
| Subserosal | On the outer surface of the uterus | Minimal impact on fertility |
| Pedunculated | Attached by stalk to outer uterine surface | Generally no fertility impact |
The FIGO (International Federation of Gynecology and Obstetrics) classification system further divides these types using a 0–8 numbering system. Submucosal fibroids are types 0–2 (type 0 = entirely within the cavity, type 2 = mostly within the wall but <50% protruding into the cavity).
The key principle from the Pritts et al. meta-analysis (2009): submucosal fibroids significantly reduce clinical pregnancy rates (relative risk approximately 0.36) and implantation rates in IVF, and their removal substantially improves outcomes. The impact of intramural fibroids that do not distort the cavity is more controversial — some meta-analyses show no effect while others show modest reductions.
How Fibroids Impair Fertility
The mechanisms by which submucosal fibroids reduce fertility include:
Altered uterine environment. Fibroids that protrude into the cavity create a mechanical obstacle and alter the endometrial surface. Blood flow patterns near the fibroid are disrupted, potentially creating hypoxic areas unfavorable to implantation.
Abnormal uterine contractility. The uterus has coordinated contractions that help transport sperm toward the tubes and guide embryo implantation. Fibroids distort this contractility pattern, potentially reducing the efficiency of both processes.
Endometrial dysfunction. Submucosal fibroids are associated with abnormal gene expression in the overlying endometrium, including alterations in receptivity markers. Even after hysteroscopic removal, the endometrium may require time to normalize.
Interference with embryo implantation. Fibroids produce local increases in inflammatory mediators and vasoactive substances that may create a hostile implantation environment even beyond the physically affected area.
Diagnosis: From Ultrasound to Saline Infusion Sonography
Transvaginal ultrasound (TVUS) is the first-line imaging modality and can detect most fibroids larger than 1–2 cm. However, standard TVUS may underestimate the degree of cavity involvement, particularly for intramural fibroids near the endometrium.
Saline infusion sonography (SIS or sonohysterography) instills sterile saline into the uterine cavity during ultrasound, distending the cavity and making it possible to visualize submucosal fibroids and polyps with much greater accuracy than standard TVUS. SIS has sensitivity and specificity for submucosal fibroids exceeding 90% and is strongly preferred in the fertility workup because it directly demonstrates cavity involvement.
MRI provides the most accurate characterization of fibroid number, size, and location — particularly for large uteri or when multiple fibroids make ultrasound interpretation difficult. MRI is also valuable for surgical planning (laparoscopic myomectomy, hysteroscopic resection) and for distinguishing fibroids from adenomyosis, which can appear similar on ultrasound.
Hysteroscopy offers direct visualization of the uterine cavity and is both diagnostic and therapeutic — submucosal fibroids can often be removed in the same procedure.
Surgical Options
Hysteroscopic Myomectomy
For submucosal fibroids (FIGO types 0–2), hysteroscopic resection is the treatment of choice. The procedure is performed through the cervix without abdominal incisions, using a resectoscope to remove the fibroid from within the cavity.
Key considerations:
- Type 0 (all within cavity) and type 1 (<50% within wall) are typically resectable in a single procedure.
- Type 2 (>50% within wall) may require a staged procedure or a more experienced surgeon.
- Recovery is generally rapid (return to normal activity within 1–2 days).
- The main risks are uterine perforation (<1%), fluid overload from distension media, and intrauterine adhesion formation.
After hysteroscopic myomectomy for submucosal fibroids, the Pritts et al. meta-analysis showed clinical pregnancy rates approaching those of women without fibroids.
Laparoscopic or Open Myomectomy
Intramural and subserosal fibroids are removed through the abdominal wall. Laparoscopic myomectomy has replaced open surgery for most cases, offering shorter recovery, less blood loss, and fewer adhesions.
Indications for myomectomy before IVF:
- Submucosal fibroid not accessible by hysteroscopy
- Large intramural fibroid (>4–5 cm) that significantly distorts the cavity
- Symptomatic fibroids causing heavy bleeding or pain, regardless of fertility plans
- Rapidly growing fibroids
Important limitations: myomectomy creates uterine scars that require healing before IVF (typically 3–6 months). Scar integrity must be assessed before embryo transfer, and patients with significant uterine incisions may be advised to deliver by cesarean section. There is also a small risk of uterine rupture in pregnancy after transmural myomectomy.
Exploring Conception Options?
Uterine fibroid treatment is one part of the fertility equation — understanding all available conception approaches helps build a complete picture.
MakeAMom makes reusable at-home insemination kits for couples and individuals trying to conceive at home: the CryoBaby for frozen or low-volume sperm, the Impregnator for low-motility sperm, and the BabyMaker for those with sensitivities. Kits ship discreetly and are designed for use without a clinic visit.
Explore home insemination kits at MakeAMom →
Fibroid Embolization: Not for Fertility-Seeking Patients
Uterine fibroid embolization (UFE) is a radiological procedure that cuts off blood supply to fibroids, causing them to shrink. It is highly effective for fibroid symptoms (heavy bleeding, pelvic pressure) in women who do not wish to preserve fertility.
UFE is not recommended for women who wish to conceive. The procedure cannot selectively embolize only fibroid vessels — it also damages the blood supply to the endometrium and potentially to the ovaries, which can impair ovarian reserve and uterine receptivity. Multiple studies document increased rates of miscarriage, placenta previa, and postpartum hemorrhage in women who conceive after UFE.
When to Operate Before IVF: A Practical Framework
The decision to remove fibroids before IVF should balance the benefit of improved implantation rates against the risks and recovery time of surgery.
Operate before IVF when:
- Any submucosal fibroid is present (types 0–2), regardless of size
- Intramural fibroid >4–5 cm with measurable cavity distortion
- Multiple intramural fibroids collectively causing significant uterine enlargement
- Previous failed IVF cycles with unexplained implantation failure and fibroids present
Observation may be appropriate when:
- Small intramural fibroids (<3 cm) that do not distort the cavity
- Subserosal fibroids of any size
- Patient is a poor surgical candidate and fibroids do not distort the cavity
- Ovarian reserve is severely diminished and time is critical (surgery delays by 3–6 months)
Success Rates After Myomectomy
Outcomes data support myomectomy for cavity-distorting fibroids:
| Situation | Approximate Clinical Pregnancy Rate per IVF Transfer |
|---|---|
| Submucosal fibroid present (untreated) | 20–28% |
| After hysteroscopic removal of submucosal fibroid | 38–50% |
| Non-distorting intramural fibroids | Similar to no-fibroid baseline |
| After laparoscopic myomectomy (large distorting intramural) | 30–45% |
These figures are approximate and age-dependent. The clearest benefit accrues from removing submucosal fibroids.
Fibroids and Pregnancy Complications
Even fibroids not removed before conception can affect pregnancy outcomes. Relevant risks include:
- Preterm labor (fibroids may stimulate uterine contractions)
- Placenta previa (if fibroid lies near the cervix)
- Fetal malpresentation (large fibroids may prevent the fetus from turning head-down)
- Fibroid degeneration during pregnancy (sudden onset of severe localized pain as fibroid outgrows its blood supply — managed with rest and analgesics)
- Increased cesarean delivery rate
Most small fibroids cause no pregnancy complications, but their presence should be documented and monitored by the obstetric team.
Choosing the Right Approach
Fibroid management in the context of fertility is best handled by a reproductive endocrinologist with access to a skilled minimally invasive gynecologic surgeon. The key questions to ask when evaluating a clinic:
- Does the practice perform hysteroscopic myomectomy, or will I be referred out?
- What threshold does the clinic use for recommending myomectomy before IVF?
- How long does the clinic recommend waiting after myomectomy before beginning IVF?
- Is MRI used for surgical planning when multiple fibroids are present?
Our guide to choosing a fertility clinic provides a comprehensive list of questions for your clinic consultation.
Frequently Asked Questions
Q: Which type of fibroid has the greatest impact on fertility? A: Submucosal fibroids — those that protrude into or distort the uterine cavity — have the clearest negative impact on fertility and IVF outcomes. A systematic review (Pritts et al., 2009) found significantly lower implantation and pregnancy rates in women with submucosal fibroids compared to those without. Subserosal fibroids (on the outer uterine wall) and intramural fibroids that do not distort the cavity have minimal impact on fertility outcomes.
Q: How does removing a submucosal fibroid affect IVF success rates? A: Hysteroscopic removal of submucosal fibroids significantly improves IVF outcomes. Clinical pregnancy rates per IVF transfer rise from approximately 20–28% with an untreated submucosal fibroid to 38–50% after hysteroscopic removal. This is among the most clearly evidence-supported interventions in fibroid management for fertility.
Q: Is uterine fibroid embolization (UFE) safe for women who want to conceive? A: No. UFE is not recommended for women who wish to conceive. The procedure cannot selectively target fibroid vessels — it also damages blood supply to the endometrium and potentially the ovaries, which can impair ovarian reserve and uterine receptivity. Multiple studies document increased rates of miscarriage, placenta previa, and postpartum hemorrhage in women who conceive after UFE. UFE is appropriate only for women with fibroid symptoms who do not plan future pregnancies.
Q: How long after myomectomy should a patient wait before starting IVF? A: Most clinics recommend waiting 3–6 months after myomectomy before beginning IVF to allow adequate uterine healing. The exact interval depends on fibroid size, number, and depth of the uterine incisions. Scar integrity should be assessed before embryo transfer, and patients with significant transmural uterine incisions may be advised to deliver by cesarean section. Failing to allow adequate healing time creates risk of uterine rupture in a subsequent pregnancy.
Q: When can intramural fibroids be observed rather than removed before IVF? A: Observation is generally appropriate for small intramural fibroids (less than 3 cm) that do not distort the uterine cavity, subserosal fibroids of any size, and cases where the patient is a poor surgical candidate and fibroids do not distort the cavity. When ovarian reserve is severely diminished and time is critical, surgery — which delays IVF by 3–6 months — may not be the best choice for small non-distorting fibroids. The decision requires individualized discussion with a reproductive endocrinologist.
Key Takeaways
- Fibroid type and location matter more than size — submucosal fibroids consistently impair fertility; subserosal and non-distorting intramural fibroids have minimal impact.
- Saline infusion sonography (SIS) is the preferred diagnostic tool for evaluating cavity involvement.
- Hysteroscopic removal of submucosal fibroids significantly improves IVF implantation rates.
- UFE is not appropriate for fertility-seeking patients.
- The decision to remove intramural fibroids before IVF requires balancing surgical risk and recovery time against the probability of implantation failure.
References
- Pritts EA, et al. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009;91(4):1215–1223.
- American Society for Reproductive Medicine. Uterine fibroids and reproductive outcomes: a committee opinion. Fertil Steril. 2017;108(3):401–407.
- Donnez J, Dolmans MM. Uterine fibroid management. Lancet. 2016;387(10021):877–887.
- Metwally M, et al. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? Fertil Steril. 2008;90(3):714–726.
- Somigliana E, et al. Should endometriomas be treated before IVF-ICSI cycles? Hum Reprod Update. 2006;12(1):57–64.
